Your browser is no longer supported. Please, upgrade your browser.
Vascular Biogenics Ltd.
Index- P/E- EPS (ttm)-0.56 Insider Own22.99% Shs Outstand47.90M Perf Week0.00%
Market Cap86.30M Forward P/E- EPS next Y-0.53 Insider Trans0.00% Shs Float37.18M Perf Month-20.96%
Income-22.70M PEG- EPS next Q-0.14 Inst Own23.90% Short Float4.79% Perf Quarter23.13%
Sales0.80M P/S107.88 EPS this Y12.60% Inst Trans0.97% Short Ratio1.60 Perf Half Y48.36%
Book/sh0.78 P/B2.32 EPS next Y1.90% ROA-47.20% Target Price- Perf Year30.22%
Cash/sh0.77 P/C2.35 EPS next 5Y- ROE-61.80% 52W Range0.90 - 3.17 Perf YTD-4.23%
Dividend- P/FCF- EPS past 5Y10.40% ROI-51.60% 52W High-42.90% Beta0.90
Dividend %- Quick Ratio5.20 Sales past 5Y- Gross Margin72.40% 52W Low101.11% ATR0.27
Employees38 Current Ratio5.20 Sales Q/Q100.00% Oper. Margin- RSI (14)35.33 Volatility11.88% 13.12%
OptionableYes Debt/Eq0.07 EPS Q/Q10.90% Profit Margin- Rel Volume0.39 Prev Close1.79
ShortableYes LT Debt/Eq0.05 Earnings- Payout- Avg Volume1.11M Price1.81
Recom1.80 SMA20-18.94% SMA50-20.29% SMA20019.18% Volume437,345 Change1.12%
Jun-27-19Initiated Oppenheimer Outperform
Mar-09-18Downgrade Chardan Capital Markets Buy → Neutral $25 → $3
Mar-08-18Downgrade Piper Jaffray Overweight → Neutral
Mar-08-18Downgrade H.C. Wainwright Buy → Neutral $3
Nov-06-17Reiterated Chardan Capital Markets Buy $20 → $25
Jun-28-16Initiated H.C. Wainwright Buy $11
Nov-09-15Initiated Piper Jaffray Overweight
Oct-23-15Reiterated Chardan Capital Markets Buy $25 → $27.50
Sep-28-15Reiterated ROTH Capital Buy $13 → $22
Sep-22-15Initiated Chardan Capital Markets Buy $25
Sep-21-15Upgrade JMP Securities Mkt Perform → Mkt Outperform
May-22-15Initiated ROTH Capital Buy $13
Mar-04-21 07:00AM  
Mar-01-21 07:00AM  
Feb-22-21 01:08PM  
Jan-27-21 07:00AM  
Jan-19-21 05:42AM  
Jan-15-21 07:15AM  
Dec-29-20 07:00AM  
Dec-07-20 07:00AM  
Nov-18-20 12:31AM  
Nov-16-20 08:25AM  
Nov-15-20 10:09AM  
Nov-13-20 10:09AM  
Nov-05-20 07:00AM  
Nov-02-20 07:00AM  
Oct-15-20 07:00AM  
Oct-13-20 07:00AM  
Oct-12-20 07:00AM  
Sep-29-20 08:00AM  
Sep-21-20 04:01PM  
Sep-17-20 02:01PM  
Sep-15-20 08:00AM  
Sep-11-20 08:00AM  
Sep-10-20 09:25AM  
Sep-08-20 08:00AM  
Aug-13-20 10:35AM  
Aug-12-20 08:00AM  
Aug-06-20 12:30PM  
Aug-03-20 08:00AM  
Jul-15-20 04:16AM  
Jun-25-20 09:02AM  
Jun-22-20 08:00AM  
Jun-04-20 07:00AM  
Jun-01-20 07:00AM  
May-28-20 09:44AM  
May-18-20 09:16AM  
May-15-20 12:28PM  
May-14-20 08:38AM  
May-13-20 06:23PM  
May-12-20 07:00AM  
May-07-20 12:30PM  
May-06-20 07:00AM  
May-05-20 10:45AM  
May-04-20 07:00AM  
Apr-21-20 07:00AM  
Apr-06-20 07:00AM  
Apr-02-20 09:00AM  
Mar-26-20 09:39PM  
Mar-21-20 09:02AM  
Mar-19-20 10:33AM  
Mar-12-20 12:30PM  
Mar-02-20 08:00AM  
Feb-20-20 08:00AM  
Feb-03-20 08:00AM  
Jan-27-20 08:29AM  
Jan-20-20 02:28PM  
Jan-08-20 08:00AM  
Nov-28-19 10:44PM  
Nov-21-19 08:00AM  
Nov-14-19 08:15AM  
Nov-07-19 10:30AM  
Nov-06-19 08:00AM  
Oct-31-19 08:00AM  
Oct-03-19 03:39PM  
Aug-13-19 08:25AM  
Aug-06-19 10:30AM  
Aug-05-19 08:00AM  
Jul-31-19 02:43PM  
Jul-22-19 08:00AM  
Jun-04-19 07:00AM  
Jun-03-19 08:00AM  
May-23-19 09:00AM  
May-16-19 07:52AM  
May-15-19 08:15AM  
May-14-19 05:16PM  
May-08-19 10:30AM  
May-06-19 08:00AM  
Apr-04-19 02:33PM  
Mar-29-19 07:19AM  
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase 3 clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase 1/2 clinical trials for recurrent platinum-resistant ovarian cancer, as well as in Phase 2 clinical trials to treat GI tumors and has completed phase 2 clinical trial for the treatment of thyroid cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; and VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases. Further, the company is developing VB-201, a Lecinoxoid-based compound used to treat atherosclerosis that has completed phase II clinical, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 and 611 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.